Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil

Journal of Smooth Muscle Research

Volumn 46, Issue 3, 2010, Pages 125-142

  Phelps, Laura E ^a   Peuler, Jacob D ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Fibrates; Rat; Smooth muscle

Indexed keywords

ARGIPRESSIN; GEMFIBROZIL; NORADRENALIN; POTASSIUM;

ANIMAL; ARTERY; ARTICLE; BLADDER; DRUG EFFECT; FEMALE; IN VITRO STUDY; MUSCLE CONTRACTION; MUSCLE RELAXATION; RAT; SMOOTH MUSCLE; SPRAGUE DAWLEY RAT; UTERUS; VASCULAR SMOOTH MUSCLE; DRUG EFFECTS;

ANIMALS; ARGININE VASOPRESSIN; ARTERIES; FEMALE; GEMFIBROZIL; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH; MUSCLE, SMOOTH, VASCULAR; NOREPINEPHRINE; POTASSIUM; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER; UTERUS; IN VITRO TECHNIQUES;

EID: 77956134224     PISSN: 09168737     EISSN: None     Source Type: Journal    
DOI: 10.1540/jsmr.46.125     Document Type: Article

References (84)

1. Agrawal, B., Kopecky, J., Kranzlin, B., Rohmeiss, P., Pill, J. and Gretz, N. (1998). Acute effects of bezafibrate on blood pressure and renal haemodynamics in SHR and WKY rats. Nephrol. Dial. Transplant. 13: 333-339.
2. Ali, S.S., Igwe, R.C., Walsh, M.F. and Sowers, J.R. (1999). Troglitazone and vascular reactivity: role of glucose and calcium. Metabolism 48: 125-130.
3. Ali, S.S., Igwe, R.C., Walsh, M.F. and Sowers, J.R. (2009) Gemfibrozil, in: Drug Information Handbook, ed. by Lacy, C.F., Armstrong, L.L., Goldman, M.P. and Lance, L.L. Lexi-Comp Inc, Hudson, p. 687.
4. Ansquer, J.C., Foucher, C., Rattier, S., Taskinen, M.R. and Steiner, G. (2005). Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 45: 485- 493.
5. Assmann, G. and Schulte, H. (1987). The prospective cardiovascular munster study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am. J. Cardiol. 59: 9G-17G.
6. Atarashi, K., Minami, M. and Takagi, M. (1993). Blood pressure reduction by bezafibrate and apoprotein B in hyperlipidemic patients with borderline hypertension. In: International Symposium on the Lipid Triad (TG, HDL, LDL) and cardiovascular disease (Abstract Book), ed. by Fondazione, Giovanni, Lorenzini and Mailand, Milan, p. 22.
7. Azadzoi, K.M., Heim, V.K., Tarcan, T. and Siroky, M.B. (2004). Alteration of urothelial-mediated tone in the ischemic bladder: role of eicosanoids. Neurourol. Urodyn. 23: 258-264.
8. 2+ stores in vascular smooth muscle: functional implications. Novartis Found. Symp. 246: 125-137.
9. Borghi, C., Dormi, A., Veronesi, M., Sangiorgi, Z. and Gaddi, A. (2004). Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am. Heart J. 148: 285-292.
10. Buckner, S.A., Milicic, I., Daza, A.V., Coghlan, M.J. and Gopalakrishnan, M. (2002). Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics and sensitivity to potassium channel modulators. Br. J. Pharmacol. 135: 639-648.
11. Bulbul, A., Yagci, A., Altunbas, K., Sevimli, A., Celik, H.A., Karadeniz, A. and Akdag, E. (2007). The role of nitric oxide in the effects of ovarian steroids on spontaneous myometrial contractility in rats. Theriogenology 68: 1156-1168.
12. Canudas, N., Vargas, F. and Miranda, M.A. (1996). Photodegradation of bezafibrate in aqueous media. Studies of its in vitro phototoxicity. Arzneimittelforschung 46: 694-697.
13. Chen, X.L. and Rembold, C.M. (1995). Phenylephrine contracts rat tail artery by one electromechanical and three pharmacomechanical mechanisms. Am. J. Physiol. 268: H74-H81.
14. Chew, G.T., Watts, G.F., Davis, T.M., Stuckey, B.G., Beilin, L.J., Thompson, P.L., Burke, V. and Currie, P.J. (2008). Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 31: 1502-1509.
15. Committee of Principal Investigators (1978). A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br. Heart J. 40: 1069-1118.
16. Criqui, M.H., Cowan, L.D., Heiss, G., Haskell, W.L., Laskarzewski, P.M. and Chambless, L.E. (1986). Frequency and clustering of nonlipid coronary risk factors in dyslipoproteinemia. The lipid research clinics program prevalence study. Circulation 73: I40-I50.
17. Cruz, J., Cruzera, A.B., Marcondes, M. and Cruz, H.M. (1990). Treatment of essential hypertension and hypercholesterolemia with or without hypertriglyceridemia, with low dose benzafibrate (200 mg/day). Rev. Hosp. Clin. Fac. Med. S. Paulo 45: 200-204.
18. De, C.C., Amiri, F., Iglarz, M., Cohn, J.S., Touyz, R.M. and Schiffrin, E.L. (2007). Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II-induced hypertension in rats. Br. J. Pharmacol. 151: 45-53.
19. Diep, Q.N., Benkirane, K., Amiri, F., Cohn, J.S., Endemann, D. and Schiffrin, E.L. (2004). PPAR( activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J. Mol. Cell Cardiol. 36: 295-304.
20. Eto, K., Ohya, Y., Nakamura, Y., Abe, I. and Fujishima, M. (2001). Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur. J. Pharmacol. 423: 1-7.
21. Fairhurst, A.S., Kent, G. and Purdy, R.E. (1981). Clofibrate and vascular smooth muscle: actions on rabbit aorta preparations. Eur. J. Pharmacol. 72: 323-329.
22. 2+ mobilization and influx in renal arteriolar contractile responses to arginine vasopressin. Am. J. Physiol. 288: F545-F551.
23. Fox, A.W., May, R.E. and Mitch, W.E. (1992). Comparison of peptide and nonpeptide receptor-mediated responses in rat tail artery. J. Cardiovasc. Pharmacol. 20: 282-289.
24. Gershon, M.D. (1981). The enteric nervous system. Annu. Rev. Neurosci. 4: 227-272.
25. Giles, T.D. and Sander, G.E. (2007). Effects of thiazolidinediones on blood pressure. Curr. Hypertens. Rep. 9: 332-337.
26. Gizard, F., Amant, C., Barbier, O., Bellosta, S., Robillard, R., Percevault, F., Sevestre, H., Krimpenfort, P., Corsini, A., Rochette, J., Glineur, C., Fruchart, J.C., Torpier, G. and Staels, B. (2005). PPAR( inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing thetumor suppressor p16INK4a. J. Clin. Invest. 115: 3228-3238.
27. Goode, G.K., Miller, J.P. and Heagerty, A.M. (1995). Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 345: 362-364.
28. Granger, S.E., Hollingsworth, M. and Weston, A.H. (1986). Effects of calcium entry blockers on tension development and calcium influx in rat uterus. Br. J. Pharmacol. 87: 147-156.
29. Graser, T., Handschuk, L. and Glusa, E. (1988). A new method for removal of vascular endothelium by saponin in isolated porcine coronary artery and rat aorta. Biomed. Biochim. Acta. 47: 79-82.
30. Grether, U., Benardeau, A., Benz, J., Binggeli, A., Blum, D., Hilpert, H., Kuhn, B., Marki, H.P., Meyer, M., Mohr, P., Puntener, K., Raab, S., Ruf, A. and Schlatter, D. (2009). Design and biological evaluation of novel, balanced dual PPAR(/( agonists. Chem. Med. Chem. 4: 951-956.
31. Haynes, J.M. and Pennefather, J.N. (1993). A1- and A2-purinoceptors in the guinea-pig uterus. Clin. Exp. Pharmacol. Physiol. 20: 609-617.
32. Henry, R.R., Lincoff, A.M., Mudaliar, S., Rabbia, M., Chognot, C. and Herz, M. (2009). Effect of the dual peroxisome proliferator-activated receptor-(/( agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 374: 126-135.
33. Iglarz, M., Touyz, R.M., Viel, E.C., Paradis, P., Amiri, F., Diep, Q.N. and Schiffrin, E.L. (2003). Peroxisome proliferator-activated receptor-( and receptor-( activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 42: 737-743.
34. Jonkers, I.J., de Man, F.H., van der Laarse, A., Frolich, M., Gevers Leuven, J.A., Kamper, A.M., Blauw, G.J. and Smelt, A.H. (2001). Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J. Hypertens. 19: 749-755.
35. Kalaitzidis, R.G., Sarafidis, P.A. and Bakris, G.L. (2009). Effects of thiazolidinediones beyond glycaemic control. Curr. Pharm. Des. 15: 529-536.
36. Kanai, A., Roppolo, J., Ikeda, Y., Zabbarova, I., Tai, C., Birder, L., Griffiths, D., de G.W. and Fry, C. (2007). Origin of spontaneous activity in neonatal and adult rat bladders and its enhancement by stretch and muscarinic agonists. Am. J. Physiol. 292: F1065-F1072.
37. Keech, A., Simes, R.J., Barter, P., Best, J., Scott, R., Taskinen, M.R., Forder, P., Pillai, A., Davis, T., Glasziou, P., Drury, P., Kesaniemi, Y.A., Sullivan, D., Hunt, D., Colman, P., d'Emden, M., Whiting, M., Ehnholm, C. and Laakso, M. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861.
38. Kelly, A.S. and Bank, A.J. (2007). The cardiovascular effects of the thiazolidinediones: a review of the clinical data. J. Diabetes Complications 21: 326-334.
39. Kilicarslan, A., Yavuz, B., Guven, G.S., Atalar, E., Sahiner, L., Beyazit, Y., Kekilli, M., Ozer, N., Oz, G., Haznedaroglu, I.C. and Sozen, T. (2008). Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome. Blood Coagul. Fibrinolysis 19: 310-314.
40. Kim, J.I., Tsujino, T., Fujioka, Y., Saito, K. and Yokoyama, M. (2003). Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens. Res. 26: 307-313.
41. Kostrzewska, A., Modzelewska, B. and Batra, S. (2000). Source of calcium for contractile responses of large and small human intramyometrial arteries. Hum. Reprod. 15: 1927-1931.
42. Kovacs, I., Toldy, E., Abel, T., Tarjan, J. and Csaszar, A. (2005). The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia. Endothelium 12: 179-183.
43. Kravtsov, G.M. and Kwan, C.Y. (1995). A revisitation on the mechanism of action of KCl-induced vascular smooth muscle contraction: a key role of cation binding to the plasma membrane. Biol. Signals 4: 160-167.
44. Kuipers, I., van der Harst, P., Navis, G., van G.L., Morello, F., van Gilst, W.H., van Veldhuisen, D.J. and de Boer, R.A. (2008). Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system. Hypertension 51: 1442-1448.
45. Kunes, J., Devynck, M.A. and Zicha, J. (2000). Chronic changes in plasma triglyceride levels do modify platelet membrane microviscosity in rats. Life Sci. 67: 959-967.
46. Leroy, M.J., Tanguy, G., Vial, M., Rostene, W., Malassine, A. and Ferre, F. (1991). The effect of vasoactive intestinal peptide (VIP) on the contractile activity of human uterine smooth muscle. Clin. Exp. Pharmacol. Physiol. 18: 205-215.
47. Liao, J., Soltani, Z., Ebenezer, P., Isidro-Carrion, A.A., Zhang, R., Asghar, A., Aguilar, E., Francis, J., Hu, X., Ferder, L. and Reisin, E. (2009). Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR(/(), improves metabolic abnormalities and reduces renal injury in obese Zucker rats. Nephron Exp. Nephrol. 114: e61-e68.
48. Mahley, R.W. and Bersot, T.P. (2006). Drug therapy for hypercholesterolemia and dyslipidemia (Chapter 35). In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, (Brunton, L.L., ed.), McGraw-Hill, New York, pp. 957-958.
49. Mamnoor, P.K., Hegde, P., Datla, S.R., Damarla, R.K., Rajagopalan, R. and Chakrabarti, R. (2006). Antihypertensive effect of ragaglitazar: a novel PPAR( and ( dual activator. Pharmacol. Res. 54: 129-135.
50. Matsui, H., Okumura, K., Kawakami, K., Hibino, M., Toki, Y. and Ito, T. (1997). Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides. Diabetes 46: 348-353.
51. + channel openers. J. Vasc. Res. 30: 2-12.
52. Miller, D.B. and Spence, J.D. (1998). Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 34: 155-162.
53. Muscari, A., Puddu, G.M. and Puddu, P. (2002). Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 97: 115-121.
54. Nakamura, Y., Ohya, Y., Onaka, U., Fujii, K., Abe, I. and Fujishima, M. (1998). Inhibitory action of insulin- sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea- pig. Br. J. Pharmacol. 123: 675-682.
55. Ogawa, H. and Tasaka, M. (1995). Lipid-regulating action of gemfibrozil in the stroke-prone spontaneously hypertensive rat. Clin. Exp. Pharmacol. Physiol. Suppl. 22: S313-S315.
56. Otsuki, M., Goya, K. and Kasayama, S. (2005). Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus. Vasc. Health Risk Manag. 1: 209-215.
57. Peuler, J.D. (2002). Differential effects of a thiazolidinedione and a biguanide on intracellular calcium dependent contractions in vascular smooth muscle. FASEB J. 16: A938.
58. Peuler, J.D., Miller, J.A., Bourghli, M., Zammam, H.Y., Soltis, E.E. and Sowers, J.R. (1997). Disparate effects of antidiabetic drugs on arterial contraction. Metabolism 46: 1199-1205.
59. Peuler, J.D. and Phelps, L.E. (2004). Attenuating effects of sildenafil on vasorelaxant properties of oral antidiabetic agents. Pharmacologist 46: 95.
60. Peuler, J.D., Warfield, R.K. and Phelps, L.E. (2004). Attenuation by 4-aminopyridine of delayed vasorelaxation by troglitazone. Metabolism 53: 147-152.
61. Remick, J., Weintraub, H., Setton, R., Offenbacher, J., Fisher, E. and Schwartzbard, A. (2008). Fibrate therapy: an update. Cardiol. Rev. 16: 129-141.
62. Roman, R.J., Ma, Y.H., Frohlich, B. and Markham, B. (1993). Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 21: 985-988.
63. Sarafidis, P.A. (2008). Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. Fundam. Clin. Pharmacol. 22: 247-264.
64. Sarafidis, P.A. and Nilsson, P.M. (2006). The effects of thiazolidinediones on blood pressure levels-asystematic review. Blood Press. 15: 135-150.
65. Schuster, H., Fagerberg, B., Edwards, S., Halmos, T., Lopatynski, J., Stender, S., Birketvedt, G.S., Tonstad, S., Gause-Nilsson, I., Halldorsdottir, S. and Ohman, K.P. (2008). Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non- diabetic subjects with insulin resistance. Atherosclerosis 197: 355-362.
66. Shatara, R.K., Quest, D.W. and Wilson, T.W. (2000). Fenofibrate lowers blood pressure in two genetic models of hypertension. Can. J. Physiol. Pharmacol. 78: 367-371.
67. Si, X., Webb, R.C. and Richey, J.M. (1999). Bezafibrate, an anti-hypertriglyceridemic drug, attenuates vascular hyperresponsiveness and elevated blood pressure in fructose-induced hypertensive rats. Can. J. Physiol. Pharmacol. 77: 755-762.
68. Sittiracha, T., McLachlan, E.M. and Bell, C. (1987). The innervation of the caudal artery of the rat. Neuroscience 21: 647-659.
69. Small, R.C. and Weston, A.H. (1971). The spontaneous electrical and mechanical activity of the longitudinal smooth muscle of the rabbit duodenum and its modification by drugs and temperature changes. J. Pharm. Pharmacol. 23: 280-287.
70. Somlyo, A.V., Woo, C.Y. and Somlyo, A.P. (1966). Effect of magnesium on posterior pituitary hormone action on vascular smooth muscle. Am. J. Physiol. 210: 705-714.
71. Souza, F.M., Padilha, A.S., Stefanon, I. and Vassallo, D.V. (2008). Differences in functional and structural properties of segments of the rat tail artery. Braz. J. Med. Biol. Res. 41: 416-423.
72. Staels, B. and Fruchart, J.C. (2005). Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460-2470.
73. Subramanian, S., DeRosa, M.A., Bernal-Mizrachi, C., Laffely, N., Cade, W.T., Yarasheski, K.E., Cryer, P.E. and Semenkovich, C.F. (2006). PPAR( activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. Am. J. Physiol. 291: E1365-E1371.
74. Szigeti, G.P., Somogyi, G.T., Csernoch, L. and Szell, E.A. (2005). Age-dependence of the spontaneous activity of the rat urinary bladder. J. Muscle Res. Cell Motil. 26: 23-29.
75. Takahashi, A. and Kushiro, T. (2008). Pioglitazone effects on blood pressure in patients with metabolic syndrome. Nippon Rinsho 66: 1591-1595.
76. Todorov, V.T., Desch, M., Schmitt-Nilson, N., Todorova, A. and Kurtz, A. (2007). Peroxisome proliferator- activated receptor-gamma is involved in the control of renin gene expression. Hypertension 50: 939-944.
77. Tordjman, K.M., Semenkovich. C.F., Coleman, T., Yudovich, R., Bak, S., Osher, E., Vechoropoulos, M. and Stern, N. (2007). Absence of peroxisome proliferator-activated receptor-( abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. Hypertension 50: 945-951.
78. Vedernikov, Y.P., Hartke, J.R., de Long, M.A., Saade, G.R. and Garfield, R.E. (2003). Sex hormone effects in non-pregnant rat and human myometrium. Eur. J. Obstet. Gynecol. Reprod. Biol. 108: 59-66.
79. Weatherford, E.T., Itani, H., Keen, H.L. and Sigmund, C.D. (2007). Is peroxisome proliferator-activated receptor-( a new "pal" of renin? Hypertension 50: 844-846.
80. Wen, X., Wang, J.S., Backman, J.T., Kivisto, K.T. and Neuvonen, P.J. (2001). Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos. 29: 1359-1361.
81. Williams, J.M., Zhao, X., Wang, M.H., Imig, J.D. and Pollock, D.M. (2005). Peroxisome proliferator- activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension 46: 366-371.
82. Wilson, T.W., Alonso-Galicia, M. and Roman, R.J. (1998). Effects of lipid-lowering agents in the Dahl salt- sensitive rat. Hypertension 31: 225-231.
83. Yagil, C. and Yagil, Y. (2007). Peroxisome proliferator-activated receptor alpha: friend or foe? Hypertension 50: 847-850.
84. Zhang, F., Sowers, J.R., Ram, J.L., Standley, P.R. and Peuler, J.D. (1994). Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24: 170-175.